Friday, 9 October 2026European Markets

EDP And EDP RENOVAVEIS Have A High Dividend Yield And Return On Equity In The Utilities Sector.

Loading stream...

(VIANEWS) - EDP (EDP.LS) is among this list of stock assets with the highest dividend rate and return on equity on the Utilities sector.

Financial Asset Price Forward Dividend Yield Return on Equity
EDP (EDP.LS) €4.77 4% 10.6%
EDP RENOVAVEIS (EDPR.LS) €19.79 0.46% 11.43%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. EDP (EDP.LS)

4% Forward Dividend Yield and 10.6% Return On Equity

EDP - Energias de Portugal, S.A. engages in the generation, transmission, distribution, and supply of electricity in Portugal, Spain, France, Poland, Romania, Italy, Belgium, the United Kingdom, Greece, Colombia, Brazil, North America, and internationally. It operates through Renewables, Networks, and Client Solutions & Energy Management segments. The company primarily generates and sells electricity through hydro, CCGT, coal, wind, solar, nuclear, and cogeneration and waste sources. It has an installed capacity of 28 GW; and operates 380,788 kilometers of distribution network lines. The company is also involved in the supply of natural gas. In addition, it offers engineering, laboratory tests, professional training, and energy services, as well as property management services. The company's electricity and gas customers include domestic, industrial, commercial, agricultural, and others. EDP - Energias de Portugal, S.A. was incorporated in 1976 and is headquartered in Lisbon, Portugal.

Earnings Per Share

As for profitability, EDP has a trailing twelve months EPS of €0.21.

PE Ratio

EDP has a trailing twelve months price to earnings ratio of 22.7. Meaning, the purchaser of the share is investing €22.7 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.6%.

Moving Average

EDP's worth is above its 50-day moving average of €4.72 and above its 200-day moving average of €4.67.

Volatility

EDP's last week, last month's, and last quarter's current intraday variation average was 0.24%, 0.01%, and 0.92%.

EDP's highest amplitude of average volatility was 0.96% (last week), 1.03% (last month), and 0.92% (last quarter).

More news about EDP.

2. EDP RENOVAVEIS (EDPR.LS)

0.46% Forward Dividend Yield and 11.43% Return On Equity

EDP Renováveis, S.A., a renewable energy company, plans, constructs, operates, and maintains electric power generation plants. The company operates wind and solar farms. As of December 31, 2021, it had an installed capacity of 5,908 megawatts in the United States; 2,194 megawatts in Spain; 795 megawatts in Brazil; and 1,142 megawatts in Portugal. The company was incorporated in 2007 and is headquartered in Madrid, Spain. EDP Renováveis, S.A. operates as a subsidiary of EDP-Energias de Portugal, S.A.

Earnings Per Share

As for profitability, EDP RENOVAVEIS has a trailing twelve months EPS of €0.64.

PE Ratio

EDP RENOVAVEIS has a trailing twelve months price to earnings ratio of 31.07. Meaning, the purchaser of the share is investing €31.07 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.43%.

More news about EDP RENOVAVEIS.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com